WynnVision Receives nearly $1.5 million for Phase II of NIH SBIR FastTrack Award
Thursday, June 6, 2019
WynnVision, a biomedical nanofilms company located in the Virginia Bio+Tech Center, received an NIH SBIR FastTrack award from the National Heart, Lung, and Blood Institute.
This funding follows an award in August 2018 for Phase I of the two-part grant in the amount of $225,000 to develop a new approach to reduce the incidence of ventilator-associated pneumonia (VAP) and ventilator-related infections. The approach, led by Dr. Olga Zolotarskaya, does not use antibiotics or antimicrobials that lead to “super-bugs.”
To receive a Phase II award speaks to the successful results of the team. “WynnVision was able to achieve milestones set in our Phase I grant, and the team is looking forward to continuing work in eliminating infections with comfort and safety for patients,” said Dr. Kenneth Wynne, founder and CEO of WynnVision.
This funding will continue WynnVision’s work with the mission of preventing infections associated with medical devices. The grant will be directed at establishing feasibility (Phase I) for reducing/preventing infections due to endotracheal tubes.
Carrie Roth, President and CEO of the VA Bio+Tech Park and Activation Capital, said, “We are proud of the work WynnVision is doing to improve patient experience by seeking solutions to infectious diseases. The Phase II award shows the strength of their work in achieving follow-on funding from the NIH.”